The integration profile of EIAV-based vectors

被引:38
|
作者
Hacker, Caroline V.
Vink, Conrad A.
Wardell, Theresa W.
Lee, Sheena
Treasure, Peter
Kingsman, Susan M.
Mitrophanous, Kyriacos A.
Miskin, James E.
机构
[1] Oxford BioMedica UK Ltd, Medawar Ctr, Oxford OX4 4GA, England
[2] Peter Treasure Stat Serv Ltd, Kings Lynn PE34 3NR, England
关键词
lentiviral vectors; EIAV; gene therapy; integration; safety;
D O I
10.1016/j.ymthe.2006.06.006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Lentiviral vectors based on equine infectious anemia virus (EIAV) stably integrate into dividing and nondividing cells such as neurons, conferring long-term expression of their transgene. The integration profile of an EIAV vector was analyzed in dividing HEK293T cells, alongside an HIV-1 vector as a control, and compared to a random dataset generated in silico. A multivariate regression model was generated and the influence of the following parameters on integration site selection determined: (a) within/not within a gene, (b) GC content within 20 kb, (c) within 10 kb of a CpG island, (d) gene density within a 2-Mb window, and (e) chromosome number. The majority of the EIAV integration sites (68%; n = 458) and HIV-1 integration sites (72%; n = 162) were within a gene, and both vectors favored AT-rich regions. Sites within genes were examined using a second model to determine the influence of the gene-specific parameters, gene region, and transcriptional activity. Both EIAV and HIV-1 vectors preferentially integrated within active genes. Unlike the gammaretrovirus MLV, EIAV and HIV-1 vectors do not integrate preferentially into the promoter region or the 5' end of the transcription unit.
引用
收藏
页码:536 / 545
页数:10
相关论文
共 50 条
  • [21] Evaluation of the production of EIAV lentiviral vectors in suspension cells
    Pearson, Laura
    Schiedner, Gudrun
    Wolfel, Jens
    Knevelman, Carol
    Pardo, Hanna
    McCloskey, Laura
    Mitrophanous, Kyriacos
    Stewart, Hannah
    HUMAN GENE THERAPY, 2014, 25 (05) : A11 - A11
  • [22] Development of an assay for quantitation of integrated EIAV vectors in vivo
    Chipchase, D. D.
    Miskin, James E.
    Day, D. M.
    Ferrige, G. L.
    Angell, D. L.
    Allen, L.
    Wardell, T. M.
    Kingsman, Susan M.
    Mitrophanous, Kyriacos A.
    HUMAN GENE THERAPY, 2007, 18 (10) : 1027 - 1027
  • [23] Evaluation of the production of EIAV lentiviral vectors in suspension cells
    Pearson, L. J. E.
    Schiedner, G.
    Wolfel, J.
    Knevelman, C.
    Pardo, H.
    McCloskey, L.
    Mitrophanous, K. A.
    Stewart, H. J.
    HUMAN GENE THERAPY, 2014, 25 (11) : A85 - A85
  • [24] EIAV-Based Retinal Gene Therapy in the shaker1 Mouse Model for Usher Syndrome Type 1B: Development of UshStat
    Zallocchi, Marisa
    Binley, Katie
    Lad, Yatish
    Ellis, Scott
    Widdowson, Peter
    Iqball, Sharifah
    Scripps, Vicky
    Kelleher, Michelle
    Loader, Julie
    Miskin, James
    Peng, You-Wei
    Wang, Wei-Min
    Cheung, Linda
    Delimont, Duane
    Mitrophanous, Kyriacos A.
    Cosgrove, Dominic
    PLOS ONE, 2014, 9 (04):
  • [25] Packaging and transfer of Gag-Pol mRNA to target cells by EIAV based lentiviral vectors
    Miskin, JE
    Chipchase, DD
    Kingsman, SM
    Mitrophanous, KA
    MOLECULAR THERAPY, 2003, 7 (05) : S176 - S177
  • [26] Development of EIAV lentiviral vectors lacking all accessory genes
    Mitrophanous, KA
    Wilkes, FJ
    Ellard, FM
    Miskin, JE
    Radcliffe, PA
    Kingsman, SM
    MOLECULAR THERAPY, 2003, 7 (05) : S183 - S184
  • [27] Optimizing EIAV vectors and delivery routes for ALS gene therapy
    Goodhead, Lucy
    Azzouz, Mimoun
    Kingsman, Susan M.
    Mitrophanous, Kyriacos A.
    Ralph, Scott
    HUMAN GENE THERAPY, 2007, 18 (10) : 1026 - 1027
  • [28] Optimizing EIAV vectors and delivery routes for ALS gene therapy
    Goodhead, L. H.
    Ning, K.
    Azzouz, M.
    Kingsman, S. M.
    Mitrophanous, K. A.
    Ralph, G. S.
    HUMAN GENE THERAPY, 2008, 19 (04) : 405 - 405
  • [29] A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors
    Miskin, J
    Chipchase, D
    Rohll, J
    Beard, G
    Wardell, T
    Angell, D
    Roehl, H
    Jolly, D
    Kingsman, S
    Mitrophanous, K
    GENE THERAPY, 2006, 13 (03) : 196 - 205
  • [30] A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors
    J Miskin
    D Chipchase
    J Rohll
    G Beard
    T Wardell
    D Angell
    H Roehl
    D Jolly
    S Kingsman
    K Mitrophanous
    Gene Therapy, 2006, 13 : 196 - 205